Neola Medical

Neola Medical EBITDA per Share

The EBITDA per Share of Neola Medical (NEOLA.ST) as of Oct 23, 2026 is -0.14 SEK. In the previous year, EBITDA per Share was -0.14 SEK — a change of 5.12% (lower).

EBITDA per Share

-0.14SEK

YoY

5.12%

Last updated:

EBITDA per Share of Neola Medical is 2025 -0.14 SEK. EBITDA per Share of Neola Medical was 2024 -0.14 SEK. It decreases by 5.12% lower compared to the previous year.

The Neola Medical EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.02 SEK
Jan 1, 2019
-0.04 SEK
Jan 1, 2020
-0.10 SEK
Jan 1, 2021
-0.40 SEK
Jan 1, 2022
-0.23 SEK
Jan 1, 2023
-0.14 SEK
Jan 1, 2024
-0.14 SEK
Jan 1, 2025
-0.14 SEK
The Neola Medical EBITDA per Share history
YEAREBITDA per ShareYoY
-0.14SEK+5.12%
-0.14SEK-5.18%
-0.14SEK-37.69%
-0.23SEK-42.94%
-0.40SEK+300.77%
-0.10SEK+148.79%
-0.04SEK+150.76%
-0.02SEK-94.31%
-0.28SEK+60.10%
-0.18SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neola Medical Stock analysis

What does Neola Medical do? Neola Medical AB commercializes medical devices based on its patented GASMAS technology for continuous lung monitoring in premature babies. The company's primary product, NEOLA, provides real-time alerts for life-threatening complications by measuring lung volume changes and oxygen concentration. Neola Medical targets neonatal intensive care units as its key market segment, serving healthcare providers who require advanced monitoring solutions for premature infants. The firm's revenue model relies on selling the NEOLA device and associated technology to hospitals and medical facilities specializing in neonatal care. The company's business concept centers on the commercialization of its medical technology product for continuous lung monitoring, leveraging the GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical focuses on the neonatal intensive care market segment, where its device offers continuous monitoring capabilities that address critical needs in premature infant care. The primary purpose of the NEOLA device is to support neonatal intensive care through real-time monitoring and alerts for complications. Neola Medical AB's revenue streams come from the sale of the NEOLA medical device and its underlying technology to healthcare institutions. The company targets neonatal intensive care units as its primary customer segment, focusing on hospitals and medical facilities that provide specialized care for premature babies. The firm's business model is built around the commercialization of its patented GASMAS technology through the NEOLA device, which addresses specific monitoring needs in neonatal care. Neola Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neola Medical stock

EBITDA per Share of Neola Medical is -0.14 SEK in 2025.

EBITDA per Share of Neola Medical changed from -0.14 SEK to -0.14 SEK, representing a 5.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Neola Medical since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Neola Medical

All Key Metrics — Neola Medical